Democratic Republic of the Congo & Mapp Biopharmaceutical
2 shared events · Importance 3 · Last updated Jul 05, 2026
Live sentiment trends, interaction importance charts, and action volume tracking available on the
Ergen Dashboard
Tech
Democratic Republic of the Congo: The Democratic Republic of the Congo is the epicenter of the Ebola outbreak and the location where the clinical trial is being conducted. The country is severely affected by the virus, with a high number of cases and deaths.
Mapp Biopharmaceutical: Mapp Biopharmaceutical developed MBP134, an experimental monoclonal antibody treatment being tested in the Ebola clinical trial. The United States government has funded research for this drug.
Apr 20, 2026 · 67 articles
Tech
Democratic Republic of the Congo: The Democratic Republic of the Congo (DRC) is experiencing the largest recorded outbreak of Ebola caused by the Bundibugyo ebolavirus, with 1,406 confirmed cases and 438 deaths. The new diagnostic test is vital for the DRC's efforts to control the outbreak.
Mapp Biopharmaceutical: Mapp Biopharmaceutical's experimental MBP134 antibody is being evaluated in a treatment trial for the Bundibugyo Ebola outbreak in the Democratic Republic of the Congo, either as a standalone treatment or in combination with Gilead Sciences' remdesivir.
Jul 02, 2026 · 8 articles
NEWSDESK
Explore this relationship live
Track how Democratic Republic of the Congo and Mapp Biopharmaceutical interact across events, view sentiment trends, and discover connected entities.
Open Dashboard